On Thursday 13 November, Biocat and CataloniaBio, with collaboration from the Barcelona Science Park, are holding the session entitled 'Different innovation models for biotechnology companies: experiences to overcome hurdles'. This will be the third session in the series Lessons Learned: Sharing experiences to boost competitiveness, an initiative that aims to promote the exchange of experiences and networking among professionals from companies in the life sciences.

”

The session will cover several different funding models for R&D-based biotechnology companies, from the classic venture capital model through a more or less committed relationship with industrial partners, as well as going public on secondary markets, with real examples explained by those who have experienced them.

This session will feature speakers like Teresa Tarragó, co-founder of IProteos, who will explain her experience with crowdfunding; Carlos Arias, CEO of iMicroQ, who will show that venture capital investment can be successful; and Luís Ruiz-Avila, CEO of Spherium Biomed, who will speak about corporate investment and the panic one feels when the investor is bigger, wiser and richer.

The audience will also hear about what it is like to go public on the MAB, what you gain and what you lose, from Miquel Àngel Bonachera, CEO of AB-Biotics —the first Catalan firm to be traded on the Alternative Stock Market (MAB). To learn when and why to seek out venture capital, or not, the session will feature the advice and opinions of Alex Casta, an investment analyst at Caixa Capital Risc. Finally, founding partner of RCD Ignasi Costas will discuss the key legal aspects of each of the funding models.

For further information [+]